Suppr超能文献

血友病患者接受骨科手术时的药物性血栓预防:2023年的文献有何说法?

Pharmacological Thromboprophylaxis in People with Hemophilia Experiencing Orthopedic Surgery: What Does the Literature Say in 2023?

作者信息

Rodriguez-Merchan Emerito Carlos

机构信息

Department of Orthopedic Surgery, La Paz University Hospital-Idipaz, 28046 Madrid, Spain.

出版信息

J Clin Med. 2023 Aug 26;12(17):5574. doi: 10.3390/jcm12175574.

Abstract

This narrative review of the literature, consisting of papers found in PubMed and The Cochrane Library published up to 31 July 2023, analyzed those that were deemed to be closely related to the title of this paper. It was encountered that the peril of deep vein thrombosis (DVT) in people with hemophilia (PWH) after orthopedic surgery is very small, such that pharmacological thromboprophylaxis is not necessary in most cases. The hemophilia literature states that the use of pharmacological thromboprophylaxis should only be performed in PWH undergoing major orthopedic surgery (total-knee arthroplasty, total-hip arthroplasty, ankle arthrodesis) who have additional venous thromboembolism (VTE) risk factors, such as old age, prior VTE, varicose veins, general anesthesia, cancer, factor V (Leiden) mutation, overweight, and treatment with the oral contraceptive pill (in females with von Willebrand's illness). If we notice various risk factors for VTE in PWH who experience orthopedic surgery, theoretically, we should perform the identical type of pharmacological thromboprophylaxis advised for non-hemophilia patients: low-molecular weight heparins (LMWHs), such as enoxaparin (40 mg subcutaneous/24 h); or direct oral anticoagulants (DOACs), either thrombin inhibitors (dabigatran, 150 mg oral/12 h) or activated factor X (FXa) inhibitors (rivaroxaban, 20 mg oral/24 h; apixaban, 5 mg oral/24 h), or subcutaneous fondaparinux (2.5 mg/24 h subcutaneously). However, the review of the literature on hemophiliac patients has shown that only a few authors have used pharmacological prophylaxis with LMWH (subcutaneous enoxaparin) for a short period of time (10-14 days) in some patients who had risk factors for VTE. Only one group of authors used a low dose of DOAC in the dusk after the surgical procedure and the next day, specifically in individuals at elevated risk of VTE and elevated risk of bleeding after the surgical procedure.

摘要

本叙述性文献综述分析了截至2023年7月31日在PubMed和考克兰图书馆中找到的与本文标题密切相关的论文。研究发现,血友病患者(PWH)骨科手术后发生深静脉血栓形成(DVT)的风险非常小,因此在大多数情况下无需进行药物预防血栓形成。血友病相关文献指出,只有在接受大型骨科手术(全膝关节置换术、全髋关节置换术、踝关节融合术)且有额外静脉血栓栓塞(VTE)风险因素的PWH中才应使用药物预防血栓形成,这些风险因素包括老年、既往VTE、静脉曲张、全身麻醉、癌症、因子V(莱顿)突变、超重以及口服避孕药治疗(患有血管性血友病的女性)。如果我们在接受骨科手术的PWH中发现各种VTE风险因素,理论上,我们应该对他们进行与非血友病患者相同类型的药物预防血栓形成:低分子量肝素(LMWHs),如依诺肝素(40mg皮下注射/24小时);或直接口服抗凝剂(DOACs),即凝血酶抑制剂(达比加群,150mg口服/12小时)或活化因子X(FXa)抑制剂(利伐沙班,20mg口服/24小时;阿哌沙班,5mg口服/24小时),或皮下注射磺达肝癸钠(2.5mg/24小时皮下注射)。然而,对血友病患者的文献综述表明,只有少数作者在一些有VTE风险因素的患者中短期(10 - 14天)使用LMWH(皮下注射依诺肝素)进行药物预防。只有一组作者在手术后黄昏和第二天对VTE风险高且手术后出血风险高的个体使用了低剂量的DOAC。

相似文献

本文引用的文献

4
Efficacy and Safety of Thromboprophylaxis Post-Orthopedic Surgery.骨科手术后血栓预防的疗效与安全性
Cureus. 2021 Nov 18;13(11):e19691. doi: 10.7759/cureus.19691. eCollection 2021 Nov.
8
Thromboprophylaxis for orthopedic surgery; An updated meta-analysis.骨科手术的血栓预防:一项更新的荟萃分析。
Thromb Res. 2021 Mar;199:43-53. doi: 10.1016/j.thromres.2020.12.007. Epub 2020 Dec 28.
10
Perioperative Venous Thromboembolism Prophylaxis.围手术期静脉血栓栓塞症预防。
Mayo Clin Proc. 2020 Dec;95(12):2775-2798. doi: 10.1016/j.mayocp.2020.06.015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验